Abstract:Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds 24e, 24m, and 25a significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Additionally, compounds 24e, 24m, and 25a markedly improved the antitumor activity of PD-1/PD-L1 blockade. In particular, compound 24e combined with the anti-PD-L1 antibody led to complete tumor regression. These results demonstrated that TLR7/8 agonists (24e, 24m, and 25a) held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00179?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00179</a>.Homology and similarity analysis between TLR7 and 8; agonistic activities of compounds 24e, 25a, and 26a in other homologous TLRs; supplementary multiplexed immunoassays for cytokines; synergy analysis of tumor size and the survival rate; representative flow cytometric analysis of tumor-infiltrating immune cells; detection of absolute counts of tumor-infiltrating immune cells and synergy analysis; relationships between the TVs and the amounts of immune cells; phospholipidosis detection of 24e, 24m, and 25a; synthesis of compounds 16a, 27, and 35; NMR spectra of target compounds; and HPLC traces of compounds 5, 24e, 24k, 24m, 25a, and 34 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_002.csv">CSV</a>)Molecular docking for GS-9620 into TLR7 and molecular docking for 17d, 24e, 24m, and 34, into TLR7 and TLR8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives Targeting TLR4−TLR4* Homodimerization via AI-Powered Next-Generation Screening

Discovery of Pyrazolo[1,5-Α]pyrimidine Derivatives Targeting TLR4-TLR4*homodimerization Via AI-powered Next-Generation Screening

Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex

Discovery of novel TLR4/MD-2 inhibitors: Receptor structure-based virtual screening studies and anti-inflammatory evaluation

Small-Molecule TLR8 Antagonists Via Structure-Based Rational Design.

Pyrimidine Triazole Thioether Derivatives As Toll‐Like Receptor 5 (tlr5)/flagellin Complex Inhibitors

Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation

Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo

Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

Computational Discovery and Experimental Confirmation of TLR9 Receptor Antagonist Leads

Design, synthesis and anti-rheumatoid arthritis activity of target TLR4 inhibitors

Design and Optimisation of a Small-Molecule TLR2/4 Antagonist for Anti-Tumour Therapy.

Discovery of Novel Ligands for TNF-α and TNF Receptor-1 Through Structure-Based Virtual Screening and Biological Assay

Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.

Exploring Species-Specificity in TLR4/MD-2 Inhibition with Amphiphilic Lipid A Mimicking Glycolipids

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors 7 and 8.

Structure-activity relationship study of dihydroartemisinin C-10 hemiacetal derivatives as Toll-like receptor 4 antagonists

Cover Picture: Pyrimidine Triazole Thioether Derivatives As Toll‐Like Receptor 5 (tlr5)/flagellin Complex Inhibitors (chemmedchem 8/2016)

Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors